NanaBidial™

NanaBidial™
Product Description

NanaBidial™ is an investigative new product containing 20 mg/mL of Cannabidiol (CBD) and and <1mg/mL of delta-9-tetrahydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.
CLINICAL TRIAL:
The buccal administration of a NanoCelle™ CBD preparation to healthy volunteers: a safety, tolerability and pharmacokinetic exploratory pilot study.

FORMULATION: 
NanaBidial™ is an investigative new product containing approximately 18:1 ratio of Cannabidiol (CBD) and delta-9-trethydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.
DATE of HREC approval 31/08/18 |NIIM EC00436 | HREC Approval ID:0049E_2018 CTN:CT‐2017‐CTN‐01923‐1 v4 | ANZCTR:ACTRN12617001491358 STUDY SITE: Scientia Clinical Research, Level 5, Bright Building, Corner High and Avoca Street, Randwick NSW 2031 Australia. STATUS: Completed


IP RIGHTS
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: AustraliaApplication number: 2016226280Filing Date: 2nd March 16 Status: Accepted
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: CanadaApplication number: 2978179Filing Date: 2nd March 16 Status: Filed
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: EuropeApplication number: 16759418.3Filing Date: 2nd March 16 Status: Under examination
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: New ZealandApplication number: 735138Filing Date:  2nd March 2016 Status: Examination Requested
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: SingaporeApplication number: 11201707068XFiling Date: 2nd March 2016 Status: Under examination
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: United StatesApplication number: 15/555038 Filing Date: 2nd March 2016Status: Under examination
Patent Title: Transmucosal and transdermal delivery systems// NanoCelleJurisdiction: Hong KongApplication number: 18103321.4Filing Date: 2nd March 2016Status: Filed

Patent Title: Protection of plant extracts and compounds from degradation API DegradationMedlab product/subject ref: API DegradationJurisdiction: AustraliaApplication number: 2017261847Filing Date: 11 May 2016Status: Accepted
Patent Title: Protection of plant extracts and compounds from degradation API DegradationMedlab product/subject ref: API DegradationJurisdiction: CanadaApplication number: 3023767Filing Date: 11 May 2016Status: Filed 
Patent Title: Protection of plant extracts and compounds from degradation API DegradationMedlab product/subject ref: API DegradationJurisdiction: EuropeApplication number: 17795190.2Filing Date: 11 May 2016Status: under examination 
Patent Title: Protection of plant extracts and compounds from degradation API DegradationMedlab product/subject ref: API DegradationJurisdiction: New Zealand Application number: 748609Filing Date: 11 May 2016Status:examination requested
Patent Title: Protection of plant extracts and compounds from degradation API DegradationMedlab product/subject ref: API DegradationJurisdiction: SingaporeApplication number: 11201809976PFiling Date: 11 May 2016Status: Under examination
Patent Title: Protection of plant extracts and compounds from degradation API DegradationMedlab product/subject ref: API DegradationJurisdiction: United StatesApplication number: 16/300537Filing Date: 11 May 2016Status: Under examination
Patent Title: Protection of plant extracts and compounds from degradation API DegradationMedlab product/subject ref: API DegradationJurisdiction: Hong KongApplication number: 19122060.7Filing Date: 11 May 2016Status: Filed

Medlab Clinical LTD

  • AU
  • 2020
    On CPHI since

Medlab Clinical LTD

  • AU
  • 2020
    On CPHI since

More Products from Medlab Clinical LTD (2)

  • NanoCBD

    Product NanoCBD

    NanoCBD is a formulation containing 16.67 mg/mL cannabidiol (CBD) as active ingredient, in a sub-micron spray applied to the oro-buccal membrane. The CBD is sourced from cannabis (hemp) strains and extracted from plant parts that produce high levels of CBD, but no THC.

    IP RIGHTS:
    Patent T...
  • MultiBiotic™

    Product MultiBiotic™

    MultiBiotic™ is an evidence-based multi-species probiotic specifically designed to target end-organ function and support gastrointestinal health and maintenance. MultiBiotic™ is an ARTG listed medicine and available in Pharmacies and HCP's in AU, NZ, SG and HK. Presently MultiBiotic™ is in Phase 1 c...

Medlab Clinical LTD resources (1)